Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces financial results for the three and nine months ended September 30, 2014 and affirms 2014 revenue guidance.
Financial highlights of the third quarter of 2014 include:
•Total revenue was $17.2 million compared with $17.5 million for the third quarter of 2013 and compared with $15.8 million for the second quarter of 2014
Help employers find you! Check out all the jobs and post your resume.
